Time to telemedicine diagnosis was found to be a useful parameter in assessing the effectiveness of telemedicine in patients who have experienced myocardial infarction.
Wearable technologies that include digital and automated health, as well as telehealth, are expected to be well integrated into cardiovascular care in the next 5 years.
The Food and Drug Administration approved the 50cc temporary Total Artificial Heart System developed and manufactured by SynCardia Systems, LLC as a bridge to heart transplant for patients who are at imminent risk for death from biventricular failure.
Patients with cardiovascular disease diagnosed with novel coronavirus (COVID-19) are urged to continue taking their angiotensin-converting enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB) medications as prescribed.
Pharmacologic cardioversion followed by electrical cardioversion and electrical cardioversion only were found to be safe and effective in patients presenting to the emergency department with recent onset acute atrial fibrillation.
Isolated diastolic hypertension, as defined in the 2017 ACC/AHA guideline was found to be more prevalent compared with IDH defined according to a 2003 recommendation.
The performance of a European Society of Cardiology algorithm in ruling out acute myocardial infarction without ST-elevation was comparable in patients with and without diabetes mellitus.
The blood levels of non-high density lipoprotein cholesterol were found to have a strong association with the long-term risk for a cardiovascular disease event.
Members of 4 societies published a consensus system of care document containing operator and institutional recommendations and requirements for transcatheter mitral valve interventions.
